Fate Therapeutics (FATE) Other Non-Current Assets (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Other Non-Current Assets came in at $10.0 million in Q1 2026, down 1.73% on a QoQ basis from $10.2 million in Q4 2025.
Fate Therapeutics (FATE) Other Non-Current Assets (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Other Non-Current Assets data on file, last reported at $10.0 million in Q1 2026.
- Quarterly Other Non-Current Assets changed N/A year-over-year to $10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (changed N/A YoY) and the FY2025 annual result came in at $10.2 million, up 113533.33% from the prior year.
- Other Non-Current Assets slipped to $10.0 million in Q1 2026, from $10.2 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $15.2 million in Q2 2022 to a low of $9000.0 in Q3 2023.
- A 5-year average of $5.8 million and a median of $33000.0 in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets jumped 169088.89% — and 2024, when it slumped 99.94%.
- Tracing FATE's Other Non-Current Assets over 5 years: stood at $15.2 million in 2022, then fell by 0.33% to $15.2 million in 2023, then tumbled by 99.94% to $9000.0 in 2024, then soared by 113533.33% to $10.2 million in 2025, then dropped by 1.73% to $10.0 million in 2026.
- The last three Other Non-Current Assets figures came in at $10.0 million (Q1 2026), $10.2 million (Q4 2025), and $9000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | 10.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.05 Mn |
| Dec 31, 2025 | 10.23 Mn |
| Dec 31, 2024 | 9,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Jun 30, 2024 | 15.18 Mn |
| Mar 31, 2024 | 9,000.00 |
| Dec 31, 2023 | 15.18 Mn |
| Sep 30, 2023 | 9,000.00 |
| Jun 30, 2023 | 33,000.00 |
| Mar 31, 2023 | 33,000.00 |
| Dec 31, 2022 | 15.23 Mn |
| Sep 30, 2022 | 33,000.00 |
| Jun 30, 2022 | 15.23 Mn |
| Mar 31, 2022 | 33,000.00 |
| Dec 31, 2021 | 33,000.00 |
| Sep 30, 2021 | 15.23 Mn |
| Jun 30, 2021 | 9,000.00 |
| Mar 31, 2021 | 9,000.00 |
| Dec 31, 2020 | 9,000.00 |
| Sep 30, 2020 | 15.23 Mn |